Related Experiment Video
Updated: Jan 8, 2026
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated
Jeffrey V Lazarus1, Leire Agirre-Garrido2, Trenton M White3
1City University of New York Graduate School of Public Health and Health Policy (CUNY SPH), New York, NY, USA; Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
Background:
An estimated one in three adults is living with metabolic dysfunction-associated steatotic liver disease (MASLD) globally, among whom 20-25% progress to metabolic dysfunction-associated steatohepatitis (MASH). Despite their hepatic and extrahepatic burden, MASLD and MASH remain absent from the WHO non-communicable disease (NCD) global action plan and its so-called best buys. This study aimed to identify MASLD and MASH interventions that can be considered as WHO best buys and determine whether they can also be quick buys (ie, interventions that can have real public health impact within 5 years).
Methods:
A core group developed 15 evidence-based intervention briefs following a literature review. These interventions were assessed for feasibility and potential impact, and whether they could also be considered as quick buys, by a global stakeholder panel in one Delphi round. Consensus was defined as 80% or higher combined agreement (ie, responses of agree plus somewhat agree).
Findings:
A total of 321 experts who worked in 85 countries participated. All 15 proposed interventions reached consensus and garnered a combined agreement higher than 86%. For 12 of the interventions, fewer than 80% of panellists selected agree, leading to a higher reliance on responses of somewhat agree to reach a high combined agreement. The highest-rated best buy was "Manage overweight, obesity, and type 2 diabetes in people living with MASLD" (99% combined agreement). "Routine screening for liver fibrosis in people living with type 2 diabetes" was the most endorsed quick buy (88%).
Interpretation:
This study shows a strong global consensus among experts that a range of interventions for MASLD and MASH meet the criteria for inclusion as WHO best buys. The high level of endorsement across the 15 interventions highlights the opportunity for global health systems to act on MASLD and MASH, providing a roadmap for policy makers to align liver health strategies with those of other NCDs. Immediate inclusion of prioritised interventions into the WHO NCD agenda could catalyse action, reduce health inequities, and strengthen the overall global response to chronic liver disease.
Funding:
Novo Nordisk and Echosens.
More Related Videos
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
01:30Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...